Full-Time

Senior Manager Software Design Quality Engineering

Dexcom

Dexcom

5,001-10,000 employees

Markets real-time CGM devices and analytics

Compensation Overview

$149k - $248.3k/yr

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Hybrid

Must live in the Pacific Time Zone and within commuting distance, typically 75 miles/120 km, of the assigned Dexcom site.

Bachelor's

Category
QA & Testing (1)
Required Skills
Microsoft Azure
Agile
Data Science
Cybersecurity
AWS
Google Cloud Platform

Get referred to Dexcom

See people who can refer or advise you

Requirements
  • At least 7 years of experience in software quality assurance or software development for medical devices, including 5 years leading high-performing teams.
  • Strong knowledge of automated testing, Agile environments, IEC 62304, and FDA guidance.
  • Expertise in Quality, Regulatory, and R&D systems within medical devices or other highly regulated industries.
  • Strong leadership and stakeholder management skills.
  • Experience analyzing business processes, designing improvements, and empowering users through training.
  • Ability to create clear documentation and presentations explaining complex strategies and technical concepts.
  • Ability to learn new technologies, adapt to changing requirements, manage multiple projects, work independently, meet deadlines, and deliver results.
  • A Bachelor's degree, preferably in an Engineering or STEM discipline.
  • 13+ years of industry experience.
  • 5–8 years of previous people management experience.
Responsibilities
  • Lead all aspects of software quality assurance and manage and mentor the QA team.
  • Oversee the partnerships component of the Quality Management System and lead a dedicated team for that function.
  • Align technology solutions with business objectives and ensure regulatory compliance.
  • Manage the software development lifecycle and define key performance metrics for reporting to senior leadership.
  • Ensure compliance with IEC 62304, FDA software validation principles, and cybersecurity guidance throughout the development process.
  • Prepare and present quality findings to executive management and R&D leadership, and monitor and resolve ongoing issues.
  • Collaborate with R&D, Operations, CyberSecurity, and V&V teams to maintain efficient, compliant development and testing processes.
  • Lead risk assessments and health hazard assessments, guide mitigation strategies, and support CAPAs as applicable.
  • Maintain validated states, review change control documentation, and present validation records during audits.
  • Promote best practices in system design and development.
  • Participate in design reviews, assist with defining software inputs, and verify outputs against requirements.
  • Identify compliance gaps, evaluate new regulations, update procedures, and support organization-wide remediation efforts related to regulatory findings.
  • Perform additional responsibilities as assigned.
Desired Qualifications
  • Proficiency in modern programming languages.
  • Experience with cloud platforms such as Azure, AWS, or Google Cloud and big data tools.
  • Familiarity with mobile and wearable software development.
  • Expertise in FDA regulations, including 21 CFR Part 11 and 21 CFR Part 820, and cybersecurity guidance.
  • Experience with BI/AI platforms.
  • Experience with mobile application development.

Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dexcom raised 2026 revenue guidance to $5.18-$5.25 billion after Q2 growth.
  • Q2 2026 revenue reached $1.31 billion, with gross margin expanding to 64.1%.
  • Dexcom secured pharmacy coverage for over seven million non-insulin patients in 2026.

What critics are saying

  • FDA classified G7 theft-related recall on June 24, 2026, risking trust and refunds.
  • Abbott settled litigation in December 2024, but CGM competition still compresses pricing.
  • G6 manufacturing ended July 1, 2026; any G7 execution failure threatens core revenue.

What makes Dexcom unique

  • Dexcom G7 15 Day launched with Health Canada approval on June 23, 2026.
  • Stelo won FDA pediatric clearance on June 23, 2026, expanding over-the-counter reach.
  • Dexcom acquired Nutrisense in June 2026, adding dietitian-guided metabolic coaching.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 12th, 2026
DexCom rallies 52.5% in three months as margins expand and earnings beat estimates

DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.

Yahoo Finance
Jul 31st, 2026
DexCom secures coverage for 7M patients, raises growth guidance after Q2 2026 results

DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.

Yahoo Finance
Jul 31st, 2026
DexCom's Q2 revenue climbs 13% to $1.31B, raises full-year guidance to $5.25B

DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.

Yahoo Finance
Jul 30th, 2026
Dexcom raises annual revenue forecast to $5.25B on strong glucose monitor demand

Dexcom raised its full-year revenue forecast on Thursday, driven by strong demand for its continuous glucose monitors. The medical device maker now expects annual revenue between $5.18 billion and $5.25 billion, up from its previous range of $5.16 billion to $5.25 billion. The company reported second-quarter revenue of $1.31 billion, a 13% increase year-over-year, beating analyst estimates of $1.29 billion. Adjusted profit reached 70 cents per share, surpassing the 61-cent estimate. Rising awareness of diabetes care, improved insurance coverage, and consumer preference for finger-prick-free technology have boosted demand for continuous glucose monitors. Dexcom competes in this market alongside Medtronic and Abbott Laboratories. Following the announcement, Dexcom's shares rose over 4% in extended trading.

Ticker Report
Jul 20th, 2026
SEB Asset Management AB Makes New $23.68 Million Investment in DexCom, Inc. $DXCM

SEB Asset Management AB purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 377,064 shares of the medical device company’s stock, valued at approximately $23,680,000. A number of other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a […]